Protalix Soars Most on Record on FDA Approval: Tel Aviv Mover – Bloomberg

Protalix Soars Most on Record on FDA Approval: Tel Aviv Mover
Bloomberg
Protalix BioTherapeutics Inc. (PLX) soared in Tel Aviv trading after the biopharmaceutical company's first product won approval from the US Food and Drug Administration. Protalix surged 14 percent to 29.14 shekels at the 4:30 pm close in Tel Aviv.
FDA OK for Gaucher drug opens new market for Pfizer, ProtalixFierceBiotech
FDA Approves New Orphan Drug to Treat a Form of Gaucher DiseaseSurfKY News
FDA approves new drug for GaucherFox News
Health.com -Xconomy -BusinessWeek
all 79 news articles »